ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos414.48 M374.09 M412.81 M414.37 M472.36 M421.91 M1.72 BInvestigación y desarrollo———————Beneficio operativo565.36 M438.94 M537.84 M505.77 M561.07 M481.89 M2.09 BTotal de ingresos no operativos-12.91 M-17.55 M-22.85 M-41.26 M-21.03 M4.47 M-80.67 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses0000000Ingresos/gastos extraordinarios-12.91 M-17.55 M-22.85 M-41.26 M-21.03 M4.47 M-80.67 MBeneficio antes de impuestos413.73 M286.33 M368.93 M308.8 M382.76 M341.23 M1.4 BParticipación en los beneficios10.31 M5.61 M7.36 M10.16 M9.87 M8.34 M35.73 MImpuestos64.49 M54.12 M93.71 M68.55 M76.73 M66.2 M305.19 MParticipación minoritaria89.92 M69.3 M75.88 M89.92 M96.81 M77.5 M340.12 MOtros ingresos/gastos después de impuestos10.74 M-7.14 M189 K-4.57 M29.07 M-6.71 M17.98 MBeneficio neto antes de actividades interrumpidas259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MOperaciones suspendidas———————Beneficio neto259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas259.33 M162.92 M199.34 M150.33 M234.22 M197.53 M781.42 MBeneficio básico por acción3.172.052.622.093.32.9310.94Beneficio por acción diluido3.0822.582.043.222.8710.71Número medio de acciones ordinarias84.99 M79.37 M75.94 M72.08 M74.23 M67.39 M—Acciones diluidas87.27 M81.28 M77.36 M73.77 M75.89 M68.88 M—EBITDA572.83 M———568.17 M——EBIT565.36 M438.94 M537.84 M505.77 M561.07 M481.89 M2.09 BCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)7.46 M———7.1 M——
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.